Longevity Stocks
The science of extending healthy lifespan.
3 Longevity Stocks companies
Longevity research has moved from science fiction to serious science. Billions are flowing into companies developing therapies that target the biology of aging itself. The goal isn't just living longer—it's extending the years of healthy, active life.
The sector includes companies working on senolytics, gene therapy, cellular reprogramming, and metabolic interventions. Some are targeting specific age-related diseases. Others are pursuing fundamental mechanisms of aging. Clinical trials are generating data that will prove or disprove decades of research.
The New Money tracks longevity companies advancing the science of healthspan. Research milestones, clinical trial progress, funding rounds, and the regulatory pathways these novel therapies must navigate. The market for not aging is potentially unlimited.
Companies in Longevity Stocks
Bristol Myers Squibb (BMS) focuses on innovative medicines for serious diseases, prioritizing strong returns and value for investors.
Hims & Hers Health, Inc. is a leading telehealth platform offering personalized health and wellness solutions, including prescription medications and over-the-counter products
Telomir Pharmaceuticals develops TELOMIR-1, a small molecule aimed at lengthening telomeres to combat age-related inflammatory conditions and promote DNA integrity.
Recent Longevity Stocks articles
Hims & Hers Is Acquiring A Blood Sampling Company
Hims & Hers (NYSE: HIMS) is acquiring Boston based blood sampling startup YourBio Health in a new all cash deal.
Eli Lilly Is Betting On Brian Armstrong’s Longevity Drug Development Startup
Eli Lilly (NYSE: LLY) has made a strategic investment of $45 million into longevity startup NewLimit at a valuation of approximately $1.6 billion.
BioAge Labs Is Making A Bold Bet On Biobank Data
BioAge Labs (NASDAQ: BIOA) has formed a new collaboration with Norway based HUNT Biobank to analyze 17,000 individual samples to develop longevity therapeutics.
Brian Armstrong Co-Founded Longevity Startup Raises Mega Round
Biotechnology startup NewLimit has raised $130M USD in a new Series B financing round led by Kleiner Perkins and notable participation from Founders Fund.
Hims & Hers Is Getting Into The Blood Testing Business
Hims & Hers (NASDAQ: HIMS) has announced they have entered into an agreement to acquire at home blood testing startup Trybe Labs.
Sam Altman Backed Longevity Biotech Startup Wants To Raise A Billion Dollars
Longevity startup Retro Biosciences has officially announced they will raise $1 billion in a new Series A financing round that includes OpenAI's Sam Altman.
OpenAI Has Ambitions For Longevity Science
OpenAI has developed a new artificial intelligence model known as GPT-4b in partnership with longevity science startup Retro Biosciences.
Hims & Hers Wants To Win The Weight Loss Opportunity
Hims & Hers Health (NYSE: HIMS) has launched a new meal subscription plan focused on providing deeper nutritional support for individuals looking to lose weight
How Telomir Pharmaceuticals Is Proving Breakthrough Longevity Science Through Dogs
Telomir Pharmaceuticals (NASDAQ: TELO) has been making potential breakthroughs in developing new therapeutics for human longevity with their novel drug.
Hevolution Foundation Is Backing A New Longevity Startup
Hevolution Foundation has announced they have led a $50 million Series A financing round for longevity biotechnology company Aeovian Pharmaceuticals.
Is Longevity For Animals The Next Big Trend In Biotech?
Animal longevity biotech startups have been rapidly accelerating, with new clinical trials underway and significant recent venture capital participation.
The Biotech Startup Reversing Cognitive Decline In Dogs
Animal Biosciences announced the first clinical evidence that their supplement designed to extend lifespan in dogs significantly improves cognitive function.
